{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:29Z","timestamp":1791169409115,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.blre.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T17:08:44Z","timestamp":1317402524000},"page":"25-32","source":"Crossref","is-referenced-by-count":86,"title":["Chemoimmunotherapy in acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Dieter","family":"Hoelzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.08.001_bb0005","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.08.001_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","article-title":"Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects","volume":"83","author":"Gokbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2011.08.001_bb0020","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.08.001_bb0025","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2011.08.001_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.08.001_bb0040","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.08.001_bb0050","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0055","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2124.2124","article-title":"CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia","volume":"116","author":"Watt","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2011.08.001_bb0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL)","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.858.858","article-title":"Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt \u2013 Like Leukemia\/Lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002","volume":"116","author":"Rizzieri","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.08.001_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.08.001_bb0095","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0100","article-title":"Immunochemotherapy with rituximab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT","volume":"94","author":"Hoelzer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.08.001_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V64.1.38.38","article-title":"Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults","volume":"64","author":"Hoelzer","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0110","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0115","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.11219","article-title":"Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311","volume":"97","author":"Szatrowski","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.08.001_bb0120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.blre.2011.08.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1926.1926","article-title":"Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 \/ MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study","volume":"112","author":"Topp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0130","unstructured":"Goekbuget N, Kneba M, Raff T, Trautmann H, Bartram C, Arnold R, et al. Molecular Response Evaluation in Adult Acute Lymphoblastic Leukemia (ALL) \u2013 Identification of a New High Risk Group and Reference Data for Future Clinical Trials. Blood 2011, submitted."},{"key":"10.1016\/j.blre.2011.08.001_bb0135","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.08.001_bb0145","article-title":"Clinical Activity of the Anti-CD19 BiTE\u00ae Blinatumomab in Patients with Relapsed\/Refractory B-precursor Acute Lymphoblastic Leukemia: Interim Results of a Phase 2 Study","author":"Topp","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.08.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.838.838","article-title":"Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)","volume":"114","author":"Stock","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0155","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.08.001_bb0160","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0165","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.leu.2403737","article-title":"Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy","volume":"19","author":"Mejstrikova","year":"2005","journal-title":"Leukemia"},{"issue":"s2","key":"10.1016\/j.blre.2011.08.001_bb0175","article-title":"Gemtuzumab Ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukemias in vitro and in vivo","volume":"90","author":"Golay","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.08.001_bb0180","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.leu.2402749","article-title":"Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin","volume":"17","author":"Zwaan","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.08.001_bb0185","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2403134","article-title":"Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation","volume":"17","author":"Balduzzi","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.08.001_bb0190","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2008.07153.x","article-title":"Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease","volume":"143","author":"Chevallier","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.08.001_bb0195","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/10428190701882161","article-title":"Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg","volume":"49","author":"Cheung","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.08.001_bb0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.21548","article-title":"Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia","volume":"84","author":"Papayannidis","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2011.08.001_bb0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.leukres.2004.08.011","article-title":"New anti-T cell immunotoxins for the clinic","volume":"29","author":"Frankel","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2011.08.001_bb0210","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0215","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.08.001_bb0220","article-title":"Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL - Children's Cancer Group 1961","volume":"96","author":"Seibel","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.08.001_bb0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00002371-200111000-00008","article-title":"Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma","volume":"24","author":"Dinndorf","year":"2001","journal-title":"J Immunother"},{"key":"10.1016\/j.blre.2011.08.001_bb0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10428199909093730","article-title":"Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy","volume":"33","author":"Uckun","year":"1999","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T03:32:55Z","timestamp":1712979175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0268960X11000658"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.08.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}